Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Social Justice Institute’s Rhonda Williams attends talk by civil rights leaders
- School of Medicine’s Max Wiznotzer weighed in on a recent study linking autism, preeclampsia
- Law’s Jonathan Adler talks federal judge’s opinion on Obama’s immigration actions
- Anthropology’s Eileen Anderson-Fye discusses her cross-cultural study of fat stigma
- Professor Deepak Sarma blogs about importance of race in studying religions